With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity,
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …

COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and
mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence …

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …

mRNA vaccines have brought about a great revolution in the vaccine fields owing to their
simplicity and adaptability in antigen design, potential to induce both humoral and cell …

This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with
hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) …